Director Atul Pande filed a Form 144 notice of proposed sale with the SEC on November 12, 2026, covering 6,000 shares of Immunovant, Inc. common stock acquired through a stock option exercise on November 11, 2026.
Key Highlights
- Proposed sale: Atul Pande, a director of Immunovant, Inc., intends to sell 6,000 shares of common stock.
- Aggregate market value: The 6,000 shares carry an aggregate market value of $214,260.00, according to the filing.
- Source of shares: The securities were acquired via exercise of stock options from the issuer on November 11, 2026, with payment made in cash.
- Approximate date of sale: November 11, 2026, executed through Morgan Stanley Smith Barney LLC Executive Financial Services.
- 10b5-1 plan: The sales are made pursuant to a Rule 10b5-1 trading plan adopted on December 26, 2025.
- Prior sales: Pande sold 1,500 shares of common stock on August 28, 2026, for gross proceeds of $64,905.00 under a 10b5-1 plan during the past three months.
- Shares outstanding: The filing reports 206,947,758 shares of common stock outstanding.
Immunovant Director Atul Pande Proposes 6,000-Share Sale via Option Exercise
According to the Form 144 filed with the SEC on November 12, 2026, Atul Pande, a director of Immunovant, Inc. (NASDAQ:IMVT), provided notice of his intent to sell 6,000 shares of the company's common stock. The filing states that the shares were acquired on November 11, 2026, through the exercise of stock options granted by the issuer, with payment made in cash on the same date. The aggregate market value of the proposed sale is listed as $214,260.00.
The filing notes that "the securities to be sold were and will be received upon the exercise of stock options over the next three months," and that "the dates of acquisition and payment were and will be the dates of exercise/sale." The proposed sale is to be conducted through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on the NASDAQ exchange. The filing further indicates that the November 11, 2026 sales are being reported on this Form 144 filed November 12, 2026 because, according to the remarks section, "the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday."
Pande's trading activity is conducted under a written Rule 10b5-1 trading plan adopted on December 26, 2025. The filing also discloses one prior sale during the past three months: 1,500 shares sold on August 28, 2026, for gross proceeds of $64,905.00, also under a 10b5-1 plan. The total shares of Immunovant common stock outstanding are reported as 206,947,758.
What Was Disclosed
Immunovant director Atul Pande filed a Form 144 notice disclosing the proposed sale of 6,000 common shares valued at $214,260.00, acquired via stock option exercise on November 11, 2026, under a 10b5-1 plan adopted December 26, 2025.




Please wait processing your request...